Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood
The phase 1b study showed a complete response (CR) rate of 46% (objective response rate of 88%) at the...